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A gene expression signature distinguishes innate response and
resistance to proteasome inhibitors in multiple myeloma
AK Mitra1, T Harding1, UK Mukherjee2,9, JS Jang3, Y Li4, R HongZheng5, J Jen3,5, P Sonneveld6, S Kumar7, WM Kuehl8, V Rajkumar7
and B Van Ness1
Extensive interindividual variation in response to chemotherapy is a major stumbling block in achieving desirable efﬁcacy in the
treatment of cancers, including multiple myeloma (MM). In this study, our goal was to develop a gene expression signature that
predicts response speciﬁc to proteasome inhibitor (PI) treatment in MM. Using a well-characterized panel of human myeloma cell
lines (HMCLs) representing the biological and genetic heterogeneity of MM, we created an in vitro chemosensitivity proﬁle in
response to treatment with the four PIs bortezomib, carﬁlzomib, ixazomib and oprozomib as single agents. Gene expression
proﬁling was performed using next-generation high-throughput RNA-sequencing. Applying machine learning-based computational
approaches including the supervised ensemble learning methods Random forest and Random survival forest, we identiﬁed a
42-gene expression signature that could not only distinguish good and poor PI response in the HMCL panel, but could also be
successfully applied to four different clinical data sets on MM patients undergoing PI-based chemotherapy to distinguish between
extraordinary (good and poor) outcomes. Our results demonstrate the use of in vitro modeling and machine learning-based
approaches to establish predictive biomarkers of response and resistance to drugs that may serve to better direct myeloma patient
treatment options.
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INTRODUCTION
Wide interindividual variation in response to chemotherapy is a
major limitation in achieving consistent therapeutic effect in many
cancers, including multiple myeloma (MM), the second-most
common hematologic malignancy with an estimated 30 330 new
cases (~2% of all new cancer cases) and 12 650 estimated deaths
in 2016 (NCI-SEER (The Surveillance, Epidemiology, and End
Results program of the National Cancer Institute) Cancer
statistics).1–4 Such heterogeneity in response to treatment is
governed in large part by the underlying molecular characteristics
of the tumor, including differences in the expression of genes
involved in mechanisms of chemoresistance.5–7 Deciphering key
changes in gene expression levels underlying personalized
sensitivity to chemotherapy is therefore essential to predict the
efﬁcacy of anticancer drugs and to prevent delay in the selection
of more effective alternative strategies
Proteasome inhibitors (PIs) are effective chemotherapeutic
agents in the treatment of MM, used alone or in combination
with other anticancer agents like alkylating agents, corticosteroids,
immunomodulatory agents and histone deacetylase inhibitors.7–9
Bortezomib (Bz/Btz/Velcade) was the ﬁrst PI to be approved by the
US Food and Drug Administration for clinical application in 2003
for the treatment of relapsed and refractory MM.10–12 Other
examples include second-generation PIs Carﬁlzomib (Cz/Cfz/
Kyprolis), Oprozomib (Opz) and Ixazomib (Ix/MLN9708/
Ninlaro).7,10,13 However, MM still remains mostly an incurable
disease with 5-year survival rate of 48.5% (NCI-SEER (The
Surveillance, Epidemiology, and End Results program of the
National Cancer Institute) Cancer statistics). Furthermore, most
MM patients ultimately undergo relapse, including patients with
good response to initial treatment who eventually develop
resistance to the therapy.7 Moreover, there are reports that
patients who fail to respond to Bz may still respond to other
PIs.8,14
Most patients receive PIs in combination with other therapeutic
agents; thus, the variability in PI response is difﬁcult to assess. In
addition, survival end points in clinical applications are measured
in months to years, and hence developing prediction algorithms
of response can be a long process.
Therefore, we utilized a collection of more than 50 human
myeloma cell lines (HMCLs) generated through the immortaliza-
tion of primary MM cells that represent a broad spectrum of the
biological and genetic heterogeneity of MM15 to create an in vitro
chemosensitivity proﬁle in response to treatment with the four PIs:
Bz, Cz, Ix and Opz as single agents. Then, we used machine
learning-based computational approaches to identify gene
signatures that could distinguish sensitive and resistant responses
in cell lines. When applied to gene expression proﬁling (GEP) data
of MM patients from four different PI-based clinical trials, our GEP
model of response/resistance to PIs successfully distinguished
differences in disease progression and distinguished extraordinary
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(good and poor) responses. Thus, these results can provide a PI
treatment-speciﬁc predictor of clinically relevant outcomes that
could affect therapeutic choices.
MATERIALS AND METHODS
Drugs
Bz (Takeda Pharmaceuticals Inc., Deerﬁeld, IL, USA) was dissolved in serum-
free RPMI-1640 (Lonza, Allendale, NJ, USA) and stored at − 20 °C. Ix
(Takeda), Cz and Opz (Amgen, Thousand Oaks, CA, USA) were dissolved in
dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA) and stored at
− 20 °C.
Cell lines
Fifty HMCLs were procured from various institutions, established and
characterized, and maintained in HMCL media with interleukin-6.16
Supplementary Table S1 provides the cytogenetic characteristics of
the HMCLs.
In vitro chemosensitivity assays
Cell cytotoxicity assays were performed on the HMCLs to create a drug
sensitivity proﬁle in response to treatment with increasing concentrations
of Bz, Cz, Ix and Opz as single agents and half-maximal inhibitory
concentration (IC50) values and area under the survival curve (AUSC) were
calculated as described earlier.16 Brieﬂy, cells were counted using Countess
automated cell counter (Invitrogen, Carlsbad, CA, USA) and seeded in 96-
well plates at a concentration of 4 × 105 cells per ml. After 24 h, cells were
treated with increasing concentrations of Bz, Cz, Ix and Opz as single
agents. Cell viability assays were performed 48 h post treatment using
CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA)
according to the manufacturer’s instructions using Synergy 2 Microplate
Reader (BioTek, Winooski, VT, USA) to generate survival curves. Percent
survival values were normalized to untreated controls and IC50 values were
determined by calculating the nonlinear regression using sigmoidal dose–
response equation (variable slope). AUSC was calculated using trapezoidal
rule and log2-transformed for further statistical analysis.
16 Caspase-3/7
activity was evaluated using Caspase-Glo 3/7 Assay kit (Promega) on
Synergy 2 Microplate Reader.
Gene expression proﬁling
RNA was isolated from six most Ix-sensitive and six most Ix-resistant cell
lines and RNA sequencing was performed on llumina HiSeq 2000 (Illumina,
San Diego, CA, USA) using 50 bp paired-end protocol with depth of 420
million reads per sample. RNA-sequencing (RNA-seq) data from CD138-
selected plasma cells were generated from MM patients enrolled in an
ongoing phase-2 Ixazomib clinical trial at Mayo Clinic (Mayo-Ix;
NCT01415882) that enrolled patients with relapsed myeloma who had
less than six cycles of prior treatment with a Bz-based regimen and were
not refractory to Bz17 (see Supplementary Methods for details).
Gene expression, treatment arm and outcome data on newly
diagnosed myeloma patients enrolled in HOVON65/GMMG-HD4 trial
(ISRCTN64455289; n= 290) were downloaded from Gene expression
omnibus (GEO) (GSE19784).18 The APEX data set (GSE9782; n=264)
consists of bortezomib-based phase-2 and phase-3 relapsed and/or
refractory myeloma clinical trials (The APEX phase-3 trial (039), a
companion study (040), the SUMMIT (025) and CREST phase-2 trials
(024)).19 For both these trials, Affymetrix, Santa Clara, CA, USA gene probe
set analysis data (U133-Plus2.0 for HOVON65/GMMG-HD4 and HG-U133A/B
for APEX) were available. Pretreatment RNA-seq data, treatment arm and
clinical outcome information on CoMMpass (Relating Clinical Outcomes in
MM to Personal Assessment of Genetic Proﬁle) trial patients were
downloaded from the MMRF (Multiple Myeloma Research Foundation)
researcher gateway portal (IA7c release; https://research.themmrf.org). The
CoMMpass Trial (NCT0145429), sponsored by MMRF, is a non-registrational,
longitudinal study of 1000 newly diagnosed MM patients followed over the
course of their disease, up to 8 years.20
Bioinformatics and statistical analysis
All statistical analyses were performed using R software environment
(https://www.r-project.org/) version 3.3.1 for statistical computing and
graphics, and GraphPad Prism v7.0 (GraphPad Software, Inc., La Jolla, CA,
USA). Spearman’s rank-order and Pearson’s product-moment correlation
analyses were performed to compare the PI responses. All tests were two
sided and Po0.05 was considered statistically signiﬁcant. Gene expression
data were preprocessed, log2-transformed and analyzed using Galaxy and
Partek Genomics Suite v6.6 (Partek Inc., St Louis, MO, USA) to perform
differential expression testing to identify gene expression signatures PI
response (details in Supplementary Methods). Analysis of variance model
or two-sided paired sample t-test was used to evaluate whether each gene
is differentially expressed. Heatmaps were generated using unsupervised
hierarchical clustering analysis based on the differentially expressed genes.
Supervised machine learning approaches construct algorithms that learn
from training data, build models based on properties of training inputs and
thus make learned predictions/decisions on new/test samples.16,21
Random forest, a supervised ensemble machine learning algorithm, was
used to establish the top differentially expressed genes as predictive GEP
signatures of PI response.21 GEP data on top Ix-sensitive vs top Ix-resistant
HMCLs (n=12) were used as ‘training data set’ to build random forest
classiﬁcation models (decision trees) and predict PI resistance of HMCLs
(n=44) in the ‘test data set’, the mRNA-seq data obtained from the
Keatslab repository (http://www.keatslab.org/data-repository). The average
bootstrap prediction error was generated using repeated bootstrapping of
the train data set with a k-fold cross-validation (k=100). The cross-
validation error rate was used to evaluate the accuracy of the method.16,21
The predictive GEP signature was then applied to the four different PI-
based MM clinical trials and random survival forest estimation method for
right censored data (randomForestSRC), another supervised machine
learning decision-tree based algorithm, was used to predict probability of
progression/event (0 = censored; 1 = progression) within the ﬁrst 3 years
for each myeloma patient.22 The predicted probability values derived using
machine learning approaches (random forest and randomForestSRC) were
rank-ordered and the predictions for the top (Q3) and bottom quantiles
(Q1) were compared with observed PI response using Somers’ Dxy rank
correlation23 (see details in Supplementary Methods).
Unsupervised K-means clustering was performed using the algorithm of
Hartigan and Wong24 to identify clinically important K-subgroups based on
our PI response GEP signature such that N/K~ 30 (N= total number of
subjects in data set). Kaplan–Meier curves for survival were generated for
the extraordinary PI response (good vs poor) clusters by computing
progression-free survival (PFS) over time.25 The Kaplan–Meier survival
curves were compared statistically using log-rank test and Cox proportion
hazard test.26 Clusters with no10 were combined for PFS comparisons.
Odds ratios (ORs) between observed clinical responses (available for
APEX and CoMMpass data sets) vs extraordinary PI-response K-means
clusters were computed using binomial logistic regression analysis (logit
model).27
Ingenuity pathway analysis
The differentially expressed genes were analyzed using Ingenuity Pathway
Analysis (IPA) to identify canonical pathways, downstream effects,
upstream regulators and causal networks and to perform predictive
toxicology analysis using toxicogenomics approaches (IPA-Tox).28
RESULTS
Wide variability in response to PI treatment
To model and characterize the interindividual variation in
therapeutic response, we assessed the in vitro PI sensitivity of a
large panel of HMCLs. Results of our cytotoxicity assays in 50
HMCLs showed a wide range of response to treatment with the
four PIs (Bz, Cz, Ix and Opz) identifying some lines that are highly
sensitive and some lines relatively refractory to PIs, as represented
by the IC50 and AUSC plots (Figures 1a and b). In some cases, the
AUSC provides a comparative measure of response through
the higher test doses, especially if an IC50 value was not achieved.
The summary table (Table 1) depicts the extensive variation in
response to each of the PIs among the panel of HMCLs. Our
caspase-3/7 activity data corroborated with cytotoxicity data (data
not shown). Figure 1c shows a correlation matrix representing
comparative analysis of IC50 values of four PIs across the HMCLs.
Statistically signiﬁcant (adjusted P-values of o0.001; Holm’s
method) positive correlation was observed between IC50 values
across the four PIs. Thus, in general, sensitivity was highly
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Figure 1. In vitro chemosensitivity proﬁles of human myeloma cell lines following proteasome inhibitor treatment. (a) Plots show survival
compared with untreated control versus increasing concentration of bortezomib, oprozomib, ixazomib and carﬁlzomib. In (b), the AUSC was
normalized and expressed as percentage of the largest value for each drug, shown for all cell lines treated with the four proteasome inhibitors.
In (c), the scatterplot matrix is shown as a pairwise correlation of the natural log (Ln) of IC50 and AUSC values for the response to each PI drug.
Scatterplot matrix was generated using the R graphing package ggplot2.
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correlated among all four PIs, especially among the cell lines
representing extraordinarily/exceptionally high and low
responses. Therefore, we evaluated bortezomib and ixazomib as
model proteasome inhibitor drugs for the gene expression
signature-based prediction of extraordinary response in PI-
inhibitor-based therapies.
However, we did ﬁnd some examples of HMCLs that were
highly sensitive to one PI, and comparably less sensitive to other
PIs. This demonstrates tumor heterogeneity even in response to
inhibitors of the same class, and further demonstrates some
tumors refractory to one PI may still respond to another.
Deriving a GEP-based signature proﬁle of PI response
We performed differential gene expression analysis between 5
(top 10%) most Ix-sensitive and 5 (bottom 10%) most Ix-resistant
cell lines. Notably, these cell lines showed the same relative
sensitivity and resistance to all four proteasome inhibitors. RNA-
seq data were preﬁltered, normalized and used for further analysis
(see Supplementary Methods). Differential gene expression
analysis was performed using the remaining 7682 genes to
identify GEP signatures that distinguish the highly sensitive from
the highly resistant HMCLs. Results showed 506 genes differed
signiﬁcantly between the sensitive and the resistant groups
(Po0.05; fold difference ≠1). In all, 141 genes showed |fold
difference| 42 and Po0.05, whereas 42 genes, listed in Table 2,
had Po0.01 (|fold difference|42) (Figure 2). Subsequent analyses
used the more stringent highly variable/differentially expressed
42-gene list. The purpose of this initial selection was to generate a
list of genes that were highly variable/differentially expressed
between PI-sensitive and PI-resistant cell lines and could then be
used in further steps to derive the prediction model and for
validation.
GEP signature of PI response is predictive of in vitro PI
chemosensitivity in HMCLs and progression in MM clinical trials
Our approach was to develop a novel methodology to predict
extraordinary/exceptional (very high and very low) PI responses in
patients using a myeloma cell line-based model system. The
training data set comprised gene expression proﬁles of HMCLs
that represent extremities of PI responses, whereas the initial
validation/test data set was derived from an independent gene
expression study on HMCLs (n= 44) performed in the Keats
laboratory at TGen laboratories (http://www.keatslab.org/data-
repository). The ﬁnal validation data set of human myeloma
patients comprised four independent clinical trials (HOVON65/
GMMG-HD4 (n= 290); APEX (n= 264); CoMMpass (n= 765); and the
Mayo-Ix trial (n= 22)).
First, the random forest algorithm for classiﬁcation was ‘trained’
using mRNA-seq data on the 42-gene signature from 6 most PI-
sensitive and 6 most PI-resistant cell lines. The out-of-bag
estimate, which is a measure of mean prediction error of the
training model calculated by subsampling the training data set,
was computed as 0%. Concurrently, the classiﬁcation error rate
derived from confusion matrix was also 0, thus validating the
Figure 1. Continued.
Table 1. Numerical summaries of chemosensitivity parameters in HMCLs
Proteasome inhibitor Mean (nM) Minimum (nM) Median (nM) Maximum (nM)
Bortezomib_ IC50 17.1 2.8 11.7 124.3
Carﬁlzomib_ IC50 10.9 0.7 7.1 55.3
Ixazomib_ IC50 155.3 15.1 42.1 4757.9
Oprozomib_ IC50 45.8 7.6 23.7 776.0
Bortezomib_ AUSC 2700.1 319.6 1524.0 38 974.0
Carﬁlzomib_ AUSC 3503.4 375.5 1448.5 19 097.0
Ixazomib_ AUSC 10 030.0 1702.0 6456.0 46 494.0
Oprozomib_ AUSC 5017.0 1050.0 2885.0 59 917.0
Abbreviations: AUSC, area under the survival curve; HMCL, human myeloma cell line; IC50, half-maximal inhibitory concentration.
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robustness of the training model. Supplementary Figure S1
provides the gene importance plot representing the most
important genes within the 42-gene expression signature
inﬂuencing PI response based on variable importance (VIMP)
measure derived from random forest analysis. The probability
scores of PI resistance were then calculated for each of the HMCLs
obtained from the Keatslab data repository (‘test’ data set). The
predicted probabilities of PI resistance were then rank-ordered
and Somers’ QUOTE rank correlation analysis was performed
between the top quantile (Q3) and bottom quantile (Q1)
resistance probability values and observed PI chemosensitivity
as a binary outcome (sensitive = 0 vs resistance = 1). Results
revealed high positive Somers QUOTE rank correlation for the PI
drug cytotoxicity parameters (IC50 and AUSC) (Table 3), indicating
that our 42-gene GEP signature validated quite well in an
independent data set of HMCLs. As the classiﬁcation model was
generated using HMCLs with top-6+bottom-6 Ix IC50 values as
training data set, the test data set for Ix IC50 prediction included
RNA-seq data on the remaining 32 cells lines only from an
independent data set obtained from the Keatslab repository.
Among these, Somers’ c value for correlation between observed Ix
IC50 and response probabilities of the top 6 predicted Ix-resistant
cell lines was 0.667 whereas it was 1.0 for the top 6 predicted Ix-
sensitive lines. Somers’ c for the combined set of 12 predicted
sensitive+resistant HMCLs was 0.743. Thus, the independent cell
line test set showed very good correlation with the signature-
derived predictor.
Although the training set showed good prediction capabilities
in an independent set of HMCLs, we were particularly interested to
determine whether it is able to stratify patient outcomes in
multiple clinical trials. Four different PI-treating trials were
examined (treatment details provided in Materials and Methods).
Microarray gene expression data from clinical trials was mean-
centered and scaled before analysis. The standardized transcrip-
tomic proﬁling data from APEX trial was used as a training data set
to perform random survival forest analysis to predict the percent
probability of a progression/event within 3 years in the HOVON-
GMMG-HD4, CoMMpass and Mayo-Ix clinical trials (test data sets).
Somers’ QUOTE rank correlation analysis between the top and
bottom quantiles of predicted percentage values from random
survival forest model on test data and the progression index of the
test data sets showed consistent positive values for the HOVON-
Table 2. List of genes most signiﬁcantly associated with proteasome inhibitor (PI) resistance (|fold difference| 42; Po0.01)
No. Gene ID P-value Fold difference (sensitive vs resistant) Fold difference (description)
1 SLC1A4 0.00004 2.695 Sensitive up vs resistant
2 NEK3 0.00006 − 2.544 Sensitive down vs resistant
3 GLA 0.00007 2.073 Sensitive up vs resistant
4 AKNA 0.00020 4.043 Sensitive up vs resistant
5 ARHGAP27 0.00035 3.599 Sensitive up vs resistant
6 LY96 0.00045 3.796 Sensitive up vs resistant
7 DLST 0.00070 − 2.001 Sensitive down vs resistant
8 MSL3 0.00132 2.237 Sensitive up vs resistant
9 SQRDL 0.00134 3.906 Sensitive up vs resistant
10 NCAPH2 0.00206 2.129 Sensitive up vs resistant
11 PLK1S1 0.00262 − 2.035 Sensitive down vs resistant
12 MRI1 0.00284 2.448 Sensitive up vs resistant
13 TARS2 0.00294 − 2.083 Sensitive down vs resistant
14 OBFC2A 0.00307 3.756 Sensitive up vs resistant
15 RAB8A 0.00319 2.097 Sensitive up vs resistant
16 ABHD2 0.00363 2.475 Sensitive up vs resistant
17 LMF2 0.00364 2.558 Sensitive up vs resistant
18 C6orf48 0.00367 − 2.462 Sensitive down vs resistant
19 TUBA4A 0.00400 2.189 Sensitive up vs resistant
20 HSPA1B 0.00467 − 2.335 Sensitive down vs resistant
21 TFEB 0.00471 − 2.302 Sensitive down vs resistant
22 RNF170 0.00504 − 2.34 Sensitive down vs resistant
23 SOX12 0.00569 − 2.281 Sensitive down vs resistant
24 ZNFX1-AS1 0.00604 − 2.482 Sensitive down vs resistant
25 C2orf69 0.00622 2.038 Sensitive up vs resistant
26 PTPN18 0.00634 2.635 Sensitive up vs resistant
27 PRKD2 0.00641 3.5 Sensitive up vs resistant
28 KHK 0.00662 2.484 Sensitive up vs resistant
29 PAQR6 0.00710 − 3.645 Sensitive down vs resistant
30 HIST1H2BD 0.00763 − 4.514 Sensitive down vs resistant
31 CERK 0.00776 2.481 Sensitive up vs resistant
32 UBE2K 0.00806 − 2.048 Sensitive down vs resistant
33 LYSMD1 0.00814 − 2.379 Sensitive down vs resistant
34 GPSM3 0.00832 5.309 Sensitive up vs resistant
35 MNAT1 0.00906 − 2.144 Sensitive down vs resistant
36 WFS1 0.00911 2.397 Sensitive up vs resistant
37 MYH9 0.00923 2.011 Sensitive up vs resistant
38 CYTIP 0.00925 2.855 Sensitive up vs resistant
39 SVIP 0.00928 2.148 Sensitive up vs resistant
40 ARSA 0.00931 3.3 Sensitive up vs resistant
41 SFMBT2 0.00947 2.111 Sensitive up vs resistant
42 POLR3GL 0.00958 − 2.251 Sensitive down vs resistant
Differential gene expression analysis was performed to compare gene expression proﬁles of 5 (top 10%) most ixazomib (Ix)-sensitive and 5 (bottom 10%) most
Ix-resistant cell lines. These 42 genes were used as gene expression proﬁling (GEP) signature of PI resistance to stratify PI response in test data sets (in vitro and
among patients).
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GMMG-HD4, CoMMpass and Mayo-Ix clinical trials revealing high
prediction accuracy of the random survival forest-based prediction
model22,23 (Table 4). Somers’ c for the training data set (APEX)
was = 0.852.
As we were particularly interested in our signature’s drug
response performance, we chose to look at progression as one
measure of response/nonresponse as well as associations that
distinguish clinical deﬁnition of response, complete response
versus nonresponse.29 K-means clustering was performed on 188
MM patients from the Bz treatment arm of the APEX data set19 to
partition the samples into clusters/subgroups based on the
expression of the 42 genes comprising the GEP signature of PI
response. Results show signiﬁcant differences in PFS between the
signature-derived poor PI-response and good PI-response groups
(hazard ratio (HR) = 2.346; P= 0.0076; Figure 3a). Conversely, no
difference in PFS is observed between the K-means clusters when
the 42-gene model was applied to the expression data of 76
patients in the dexamethasone arm of APEX phase-3 trial that
compared single-agent Bz with high-dose dexamethasone (HR =
1.1; P= 0.732; Figure 3a), showing our GEP signature is drug
Figure 2. Heatmap representing differential gene expression between PI-sensitive and PI-resistant myeloma cell lines. Gene expression was
z-score normalized (standardized: shifted to mean of 0 and scaled to s.d. of 1) and compared among the ﬁve most Ix-responsive and ﬁve least
Ix-responsive cell lines. Heatmap was generated using the top 42 differentially expressed genes (|fold difference|42; Po0.01). Columns are
ordered by Ix IC50 of cell; genes are ordered by fold difference. Color indicates fold change between Ix-resistant and Ix-sensitive cell lines.
Table 3. Summary of correlation between predicted probabilities of PI
resistance and observed PI cytotoxicity values
Somers' c Spearman's ρ
cQ3 cQ1 CQ3+Q1 SpearmanQ3+Q1 P
Bz_IC50 0.643 0.786 0.852 0.748 0.00036
Cz_IC50 0.714 0.524 0.750 0.563 0.00981
Opz_IC50 0.667 0.944 0.802 0.626 0.00548
Bz_AUSC 0.643 0.786 0.852 0.736 0.00050
Cz_AUSC 0.595 0.667 0.712 0.601 0.00507
Ix_AUSC 0.857 0.889 0.927 0.765 0.00009
Opz_AUSC 0.667 0.786 0.813 0.630 0.00509
Abbreviations: AUSC, area under the survival curve; Bz, bortezomib; Cz,
carﬁlzomib; IC50, half-maximal inhibitory concentration; Ix, ixazomib; Opz,
oprozomib; PI, proteasome inhibitor. Random forest classiﬁcation model
was generated using human myeloma cell lines (HMCLs) with top-6
+bottom-6 Ix IC50 values as training data set. Predicted probability values
of HMCLs in the test data set were rank-ordered and Somers’ Dxy rank
correlation analysis was performed between the top quantile (Q3) and
bottom quantile (Q1) resistance probability values observed PI chemo-
sensitivity as a binary outcome (sensitive= 0 vs resistance= 1). Spearman’s
rank-ordered correlation was performed in cell lines representing Q3 and
Q1 probabilities of resistance and corresponding cytotoxicity values.
Table 4. Summary of Somers’ Dxy rank correlation analysis between
predicted probability values of progression (derived from random
survival forest model) and the progression index of MM patients from
PI-based clinical trials (test data sets)
Somers' c
cQ3 cQ1 CQ3+Q1
HOVON-GMMG-HD4 (PAD arm) 0.596 0.599 0.561
CoMMpass–Bz ﬁrst-line therapy 0.705 0.469 0.595
CoMMpass–Len ﬁrst-line therapy 0.320 0.203 0.262
Mayo-Ix 0.500 0.833 0.680
APEX-Dex arm 0.365 0.467 0.431
Abbreviations: Bz, bortezomib; Cz, carﬁlzomib; Dex, dexamethasone; Ix,
ixazomib; Len, lenalidomide; MM, multiple myeloma; PAD, bortezomib,
doxorubicin and dexamethasone; PI, proteasome inhibitor. Transcriptomic
proﬁling data from APEX trials were used as training data set.
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Bortezomib/Bz arm Dexamethasone/Dex arm
PAD (Bortezomib, Doxorubicin, Dexamethasone) arm Vincristine, Doxorubicin, Dexamethasone (VAD) arm 
Len as first line of therapyBz as first line of therapy
a
b
c
Good PI-response cluster (n =10)
Poor PI-response cluster (n =9)
d
Figure 3. Plots showing stratiﬁcation in progression-free survival (PFS) among MM patients on PI-based clinical trials in which the 42-gene
model was used to assign extraordinary (good and poor) PI response. Kaplan–Meier survival curves in (a) APEX data set: bortezomib arm
shows signiﬁcant separation of PFS between clusters representing good vs poor outcomes, whereas the dexamethasone arm shows no
stratiﬁcation; (b) patients in the HOVON-GMMG-HD4 trial (Bz-treated/PAD and VAD arms) were assigned good versus poor PI response
based on the 42 gene model. PFS curves for the interim analysis of the (c) CoMMpass trial (NCT0145429) patients administered Bz or
Lenalidomide (Len) as ﬁrst-line therapy and (d) the Mayo Clinic Ix-trial (NCT01415882). Patients were assigned good versus poor
response based on the 42-gene model. Inset of (d) shows survival of each patient considered. Dashed line represents end of year 1
(365.25 days from randomization).
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speciﬁc. Concurrently, statistically signiﬁcant association is
observed between the K-means clusters and clinical response in
the Bz arm (ORresponder vs nonresponder = 5.813; 95% conﬁdence
interval = 1.833–20.007; POR = 0.0036) but not in the Dex arm
(ORresponder vs nonresponder = 2.139; 95% conﬁdence interval = 0.753–
6.326; POR = 0.158) of the APEX data set.
When applied to the gene expression data from HOVON-
GMMG-HD4 clinical trial (n= 290) that implemented a Bz-based
drug regimen,18 the 42-gene signature shows statistically sig-
niﬁcant differences in PFS among K-means clusters representing
good vs poor PI response in the Bz-treated PAD (bortezomib,
doxorubicin and dexamethasone) arm (HR= 2.161; P= 0.024),
whereas no difference in PFS is observed in the VAD (vincristine,
doxorubicin and dexamethasone) arm (HR= 1.282; P= 0.437;
Figure 3b). What is particularly striking is that within the ﬁrst 1.5
years the predicted good response group in the PI-containing
therapy had no progression events, whereas 35% of the predicted
poor response group had progression events.
Clinical data were available on 765 patients from the CoMMpass
study. A total of 253 patients used Bz as ﬁrst-line therapy, alone or
in combinations. Of these, 128 had RNA-seq and PFS data
available. K-means clustering based on the expression of the 42
genes distinguishes between good and poor PFS subgroups of
myeloma patients (HR = 2.556; P= 0.0277; Figure 3c). In addition,
the K-means clusters are also found associated with clinical
response (OR= 5.20; 95% conﬁdence interval = 1.22 36.077;
POR = 0.0453). In contrast, among the 96 patients using Lenalido-
mide (an immuno-modulatory drug) as ﬁrst-line therapy, no
association was observed between the good and poor K-means
clusters and PFS (P= 0.49; Figure 3c). Our results thus further
validate the PI response speciﬁcity of our method.
Finally, we applied our algorithm based on the our 42-gene PI
response signature to an ongoing clinical trial at Mayo Clinic that
uses Ix-containing drug regimen. Interestingly, even with small
numbers of patients available, our GEP-based PI response classiﬁer
distinguishes between the top (medium PFS= 22.42 months) and
bottom responders (medium PFS = 12 155 months) in this Ix trial
(risk ratio = 2.5) (Figure 3d). Notably, all 10 patients in the good
performance group were alive at the latest point of the interim
analysis, whereas 4 out of 9 patients in the poor PI response
cluster died (inset of Figure 3d).
Ingenuity pathway analysis
Genes in the 42-gene GEP model were then analyzed using IPA to
assign them to different functional networks. Out of the 42 genes,
12 overlapped with the top IPA network obtained from the
analysis of direct and indirect relationships (score = 26), as
represented in Supplementary Figure S2a. Genes/molecules in
this network include the 26s proteasome complex. Furthermore,
when we used the IPA upstream regulator analysis, TFEB and
CCND1 were identiﬁed as the top hits/factors that may control the
genes and pathways highlighted by network analysis
(Supplementary Figure S2b). The functional signiﬁcance is
discussed further in the Discussion.
DISCUSSION
Resistance to chemotherapy in cancers is a major limitation in
achieving complete and sustained therapeutic effect, and may in
fact lead to unwanted exposure to ineffective antitumor agents,
thereby increasing the risk of negative side effects.1 MM is a
mostly incurable disease with a median overall survival of 4.6
years despite signiﬁcant improvement in treatment strategies over
the past 12 years.2–4,30,31 Differential GEP studies have provided
GEP signatures as a useful prognostic indicator of low- versus
high-risk MM; however, none of these gene signatures were
treatment speciﬁc.15,18,32 Furthermore, no study thus far has made
use of the vast array of HMCLs as model system to generate drug
chemosensitivity proﬁle as a representation of the response
variation in patient subtypes that may be used to derive a PI-
speciﬁc GEP signature predictive of resistance and treatment
outcomes.
In the current study, using a panel of 50 HMCLs, we successfully
developed an in vitro chemosensitivity proﬁle to four PI
treatments. We focused on common features that distinguish
the most and least responsive HMCLs, noting that these responses
are very similar across all four PIs. However, several outliers
(HMCLs that were highly resistant to one PI and highly sensitive to
another) were noted. Interestingly, several cell lines with
intermediate response to Bz or Ix were found highly responsive
to Cz treatment. However, in general the ranked correlation with
response was very similar among all four PIs, particularly those
lines that were collectively the most responsive and least
responsive to all four PIs (extraordinary responders). Further
characterization of the outliers may reveal important features that
better direct which PI is most effective.
Using transcriptomic proﬁling of PI-sensitive vs PI-resistant
HMCLs followed by extensive machine learning-based response
prediction, we demonstrate here a gene expression signature that
distinguishes strong sensitivity versus strong resistance to the four
PIs when used in MM. Importantly, this signature was not applied
across the full range of responses, but was very effective in
identifying extraordinary (good versus poor) response. We also
observed that this 42-gene signature of innate PI response is
different from a signature of acquired PI response that we
generated by comparing GEP between PI-sensitive and subse-
quent resistant outgrowths of Bz-resistant MM cell lines
(unpublished data).
Despite the small numbers of cell lines used to generate the 42-
gene signature, when applied to clinical trials on MM patients
undergoing PI-based therapies, our GEP signature was remarkably
correlated with extraordinary PI response/resistance, could predict
early or late progression events and efﬁciently clustered patient
responses into favorable (response or complete response) vs
unfavorable (nonresponse) outcome subgroups. Notably, the GEP
signature did not stratify response to non-PIs in the APEX, HOVON
and CoMMpass trials, suggesting PI treatment speciﬁcity, not
simply high- versus low-risk tumor biology irrespective of drug
treatment regimen as has been previously reported.32
Several genes included in our GEP signature have been
previously implicated with prognosis and disease progression in
myeloma. For example, the cell cycle regulator CCND1 (cyclin-D1)
has been reported as a strong prognostic predictor in multiple
studies.15,16 HSPA1B is an NRF2-mediated oxidative stress
response gene that was also found signiﬁcant (Po0.001; |fold
change| 42) in our earlier study that compared differential
responsiveness with Bz in vitro.33 Abnormal levels of serum bone
Gla protein have been shown to play important role in the
inhibition of bone formation in the occurrence of bone lesions in
MM that may have prognostic implications.34 Wolfram syndrome 1
encodes an endoplasmic reticulum (ER) transmembrane protein
that plays a role in regulation of ER stress signaling and in the
pathogenesis of diseases involving chronic, unresolvable ER
stress.35 Furthermore, Wolfram syndrome 1 is a downstream
transcriptional target of the gene X-box binding protein (XBP1), a
bZIP transcription factor that regulates unfolded protein response
and ER stress-induced apoptosis.35,36 Higher expression of XBP1
pathway genes is associated with better outcome/response in PI-
treated MM patients, whereas loss of XBP1 has been shown to
induce PI resistance.36,37 Interestingly, we found that the unspliced
transcript of XBP1 (Xbp1u) had ~ 1.5 times lower expression in Ix-
resistant cell lines when compared with Ix-sensitive cell lines. The
transcription factor EB (TFEB) is a master gene for lysosomal
biogenesis that drives expression of a large subset of autophagy
genes leading to activation of autophagic cell death of myeloma
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cells owing to metabolic cell stress.38 RNF170 encodes an ER
membrane ubiquitin ligase that mediates ubiquitination and
degradation and plays a key role in cell signaling.39 Given previous
reports on the association of these genes to myeloma biology and
outcomes, we considered their collective inclusion in our
unsupervised clustering further validation of their role in PI
response. Although individually associated with MM biology, our
GEP signature suggests a combination of effectors inﬂuence
response to PIs. Additional studies will be required to functionally
validate the combined effects of these genes towards response to
PI-based therapy.
Earlier, we demonstrated that gene expression signatures may
be used to identify secondary therapies in PI-resistant MM using in
silico predictions that were conﬁrmed in vitro.33,40 In 2014, the NCI
initiated the Exceptional Responders Initiative to understand the
molecular basis of exceptional response to chemotherapy in
cancer patients enrolled in clinical trials.41 The primary goal of the
study is to identify molecular features in malignant tissue that may
aid to predict response to same or similar drugs. On similar lines,
our work should serve as resource to use machine learning-based
approaches for the personalized prediction of exceptional
chemoresistance and to eventually identify signatures of drug
combination regimens that may effectively reverse drug resis-
tance by predicting drugs for various subpopulations/subclones of
tumors based on pharmacogenomic signature proﬁles.
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